Phase III study in ARC patients terminated due to insufficient evidence of the drug's effectiveness in combating the AIDS virus. In a Oct. 13 joint release, the companies attributed the cancellation to "an interim analysis of the AMP 101 data [which] has failed to show any difference between Ampligen and placebo that would justify continuation of the study." The AMP 101 placebo controlled trial involved 330 patients with ARC at 11 medical centers nationwide. DuPont earlier dissolved the joint venture with the Philadelphia, Penn.-based HEM but agreed to continue supplying the anti-AIDS drug for the study ("The Pink Sheet" Aug. 22, T&G-1).
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.